Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

ACOG - Alpha Cognition Inc. Latest News | Finranks

Home

ACOG

(ACOG)

NCM – Real Time Price. Currency in USD

5.08

-0.26 (-4.87%)

At close: Mar 27, 2026, 4:00 PM EDT

5.08

0.00 (0.00%)

After-hours: Mar 27, 2026, 4:10 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Alpha Cognition Inc. (ACOG) Q4 2025 Earnings Call Transcript

Alpha Cognition Inc. (ACOG) Q4 2025 Earnings Call Transcript

Alpha Cognition Inc. (ACOG) Q4 2025 Earnings Call Transcript

Alpha Cognition Inc. (ACOG) Reports Q4 Loss, Lags Revenue Estimates

Alpha Cognition Inc. (ACOG) Reports Q4 Loss, Lags Revenue Estimates

Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.51 per share a year ago.

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (ACOG: NASDAQ) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “2025 was a year of strong commercial execution for Alpha Cognition as we continued to build momentum for ZUNVEYL – the f.

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its fourth quarter and full year financial results and business highlights o.

Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences

Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists (AAGP), taking place April 16-20, 2026 and the Neuroscience Education Institute (NEI) Spring Congress, taking place May 1-3, 2026. The.

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting. The BEACON study is designed to assess the real-world imp.

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled “Dosage Regimens for Benzgalantamine.” The issued patent includes claims covering methods of orally admin.

Videos

No Data

There is no data to display